2022
DOI: 10.3389/fmed.2022.1059612
|View full text |Cite
|
Sign up to set email alerts
|

Treatment of cutaneous vasculitis

Abstract: Cutaneous vasculitis encompasses a spectrum of disease states, with varied morphology, severity, and potential for systemic involvement. Even vasculitis which is skin-limited can have a significant quality-of-life impact, necessitating treatment. This manuscript summarizes the available evidence for management of various types of skin-limited vasculitis and provides a proposed therapeutic ladder based on published studies and expert opinion.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
3
1
1
1

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(1 citation statement)
references
References 64 publications
0
1
0
Order By: Relevance
“…In addition to these medications, we introduced dapsone and hydroxychloroquine as adjuncts, given their well-established immunosuppressive effects in vasculitis and pyoderma gangrenosum [ 11 , 18 ].…”
Section: Discussionmentioning
confidence: 99%
“…In addition to these medications, we introduced dapsone and hydroxychloroquine as adjuncts, given their well-established immunosuppressive effects in vasculitis and pyoderma gangrenosum [ 11 , 18 ].…”
Section: Discussionmentioning
confidence: 99%